rituximab
not tagged
['valent ,(-prevalent)']
ielsg37 topline results
- pfs equivalent* between rt vs no-rt arms (*or as close to equivalent as possible in such a rare disease)
- os very impressive &gt;95%
- some concern that the ds4 patients (who were not included in randomisation here) are still being overtreated
#17icml 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem